New
For roughly 15 years, Prof. John Harris, MD, Chair of Vitiligo Clinic and Research Center at the University of Massachusetts Medical School has been intensely studying the pathogenesis of vitiligo, and working on potential treatments.
In this 30-min audio interview with Dr. Brad Glick from HCP Live, Prof. Harris provided insight into his decades on research of inflammatory skin disorders. He also offered an in-depth analysis on the most recent data surrounding vitiligo, and promising new therapies involving topical steroids, JAK inhibitors and more.
FAQOther Questions
- What is the best therapy for localized vitiligo?
Localized vitiligo, where the white patches are limited to one or a few areas of the body, can be managed with a few treatment approaches. The best therapy usually depends on th...
- What are risks of oral and topical corticosteroids?
Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...
- Can chemicals cause vitiligo?
It’s important to remember there are multiple factors involved in vitiligo onset, including genetic predisposition, living and working environments, and exposure to certain chem...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.